Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
A restricted sequential design multicentre controlled trial of yttrium-90 against triamcinolone intra-articularly was undertaken in patients with rheumatoid arthritis with knee involvement. The trial had to be discontinued because of dwindling recruitment over time. The reasons for this and other features contributing to an inconclusive outcome are noted. This experience lends little encouragement to the idea that yttrium-90 therapy is more or less advantageous than triamcinolone hexacetonide.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on